ProPhase Labs, Inc.
ProPhase Labs, Inc. (PRPH): 3 pipeline candidates · ~3 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.5 months
D/E 16.07 · 0% dilution
Lead: Preclinical
3 candidates
N/A
N/A
A transparent, data-derived signal for ProPhase Labs, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.1M
Cash
$90K
Quarterly Burn
$1.2M
Runway
2.5 mo
Revenue
$784K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Frequently asked questions
How many drug candidates are in ProPhase Labs, Inc.'s pipeline?
ProPhase Labs, Inc. (PRPH) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ProPhase Labs, Inc.'s lead drug candidate?
ProPhase Labs, Inc.'s most advanced tracked candidate is be-smart (Preclinical) for Early detection of progression from Barrett's esophagus to esophageal adenocarcinoma.
What is ProPhase Labs, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ProPhase Labs, Inc. has approximately 2.5 months of cash runway.
What is ProPhase Labs, Inc.'s market capitalization?
ProPhase Labs, Inc.'s market capitalization is approximately $1.1M.
Who is the CEO of ProPhase Labs, Inc.?
Mr. Ted William Karkus is the chief executive officer of ProPhase Labs, Inc. (PRPH).
Get the full picture on ProPhase Labs, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.